02758nas a2200373 4500008004100000022001400041245009300055210006900148260001500217300001400232490000700246520158800253653002801841653001101869653003501880653002401915653001801939653001301957653001701970653001801987653002202005100001702027700002102044700002102065700002002086700002902106700002002135700002202155700002002177700001902197700001702216700002302233856012802256 2020 eng d a1549-491800aPlatform to study intracellular polystyrene nanoplastic pollution and clinical outcomes.0 aPlatform to study intracellular polystyrene nanoplastic pollutio c2020 10 01 a1321-13250 v383 a
Increased pollution by plastics has become a serious global environmental problem, but the concerns for human health have been raised after reported presence of microplastics (MPs) and nanoplastics (NPs) in food and beverages. Unfortunately, few studies have investigate the potentially harmful effects of MPs/NPs on early human development and human health. Therefore, we used a new platform to study possible effects of polystyrene NPs (PSNPs) on the transcription profile of preimplantation human embryos and human induced pluripotent stem cells (hiPSCs). Two pluripotency genes, LEFTY1 and LEFTY2, which encode secreted ligands of the transforming growth factor-beta, were downregulated, while CA4 and OCLM, which are related to eye development, were upregulated in both samples. The gene set enrichment analysis showed that the development of atrioventricular heart valves and the dysfunction of cellular components, including extracellular matrix, were significantly affected after exposure of hiPSCs to PSNPs. Finally, using the HiPathia method, which uncovers disease mechanisms and predicts clinical outcomes, we determined the APOC3 circuit, which is responsible for increased risk for ischemic cardiovascular disease. These results clearly demonstrate that better understanding of NPs bioactivities and its implications for human health is of extreme importance. Thus, the presented platform opens further aspects to study interactions between different environmental and intracellular pollutions with the aim to decipher the mechanism and origin of human diseases.
10aEnvironmental Pollution10aHumans10aInduced Pluripotent Stem Cells10aIntracellular Space10aNanoparticles10aPlastics10aPolystyrenes10aTranscriptome10aTreatment Outcome1 aBojic, Sanja1 aFalco, Matias, M1 aStojkovic, Petra1 aLjujic, Biljana1 aJankovic, Marina, Gazdic1 aArmstrong, Lyle1 aMarkovic, Nebojsa1 aDopazo, Joaquin1 aLako, Majlinda1 aBauer, Roman1 aStojkovic, Miodrag uhttps://www.clinbioinfosspa.es/content/platform-study-intracellular-polystyrene-nanoplastic-pollution-and-clinical-outcomes03269nas a2200685 4500008004100000022001400041245011800055210006900173260001500242300000900257490000700266520115400273653001901427653005101446653001701497653002201514653002101536653002601557653002201583653002001605653003001625653001901655653001301674653001101687653003101698653001301729653001401742653002101756653003501777653004101812653002201853100002301875700001701898700001901915700001801934700002301952700001901975700001501994700001702009700001602026700002002042700001602062700002402078700001902102700001802121700002402139700001802163700002502181700001702206700001902223700002302242700002702265700002002292700002502312700002002337700002102357700002602378710005702404856012202461 2019 eng d a2041-172300aCommunity assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.0 aCommunity assessment to advance computational prediction of canc c2019 06 17 a26740 v103 aThe effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells.
10aADAM17 Protein10aAntineoplastic Combined Chemotherapy Protocols10aBenchmarking10aBiomarkers, Tumor10aCell Line, Tumor10aComputational Biology10aDatasets as Topic10aDrug Antagonism10aDrug Resistance, Neoplasm10aDrug Synergism10aGenomics10aHumans10aMolecular Targeted Therapy10amutation10aNeoplasms10apharmacogenetics10aPhosphatidylinositol 3-Kinases10aPhosphoinositide-3 Kinase Inhibitors10aTreatment Outcome1 aMenden, Michael, P1 aWang, Dennis1 aMason, Mike, J1 aSzalai, Bence1 aBulusu, Krishna, C1 aGuan, Yuanfang1 aYu, Thomas1 aKang, Jaewoo1 aJeon, Minji1 aWolfinger, Russ1 aNguyen, Tin1 aZaslavskiy, Mikhail1 aJang, In, Sock1 aGhazoui, Zara1 aAhsen, Mehmet, Eren1 aVogel, Robert1 aNeto, Elias, Chaibub1 aNorman, Thea1 aK Y Tang, Eric1 aGarnett, Mathew, J1 aDi Veroli, Giovanni, Y1 aFawell, Stephen1 aStolovitzky, Gustavo1 aGuinney, Justin1 aDry, Jonathan, R1 aSaez-Rodriguez, Julio1 aAstraZeneca-Sanger Drug Combination DREAM Consortium uhttps://www.clinbioinfosspa.es/content/community-assessment-advance-computational-prediction-cancer-drug-combinations02950nas a2200445 4500008004100000022001400041245009500055210006900150260001500219300001400234490000700248520156700255653002101822653002101843653002401864653003001888653004301918653002901961653001101990653002602001653001502027653001302042653001402055653001402069653001402083653001402097653002702111653002702138653001802165653002202183100001802205700002202223700001902245700002202264700002102286700002002307700003102327700002002358856012602378 2018 eng d a1538-744500aGene Expression Integration into Pathway Modules Reveals a Pan-Cancer Metabolic Landscape.0 aGene Expression Integration into Pathway Modules Reveals a PanCa c2018 11 01 a6059-60720 v783 aMetabolic reprogramming plays an important role in cancer development and progression and is a well-established hallmark of cancer. Despite its inherent complexity, cellular metabolism can be decomposed into functional modules that represent fundamental metabolic processes. Here, we performed a pan-cancer study involving 9,428 samples from 25 cancer types to reveal metabolic modules whose individual or coordinated activity predict cancer type and outcome, in turn highlighting novel therapeutic opportunities. Integration of gene expression levels into metabolic modules suggests that the activity of specific modules differs between cancers and the corresponding tissues of origin. Some modules may cooperate, as indicated by the positive correlation of their activity across a range of tumors. The activity of many metabolic modules was significantly associated with prognosis at a stronger magnitude than any of their constituent genes. Thus, modules may be classified as tumor suppressors and oncomodules according to their potential impact on cancer progression. Using this modeling framework, we also propose novel potential therapeutic targets that constitute alternative ways of treating cancer by inhibiting their reprogrammed metabolism. Collectively, this study provides an extensive resource of predicted cancer metabolic profiles and dependencies. Combining gene expression with metabolic modules identifies molecular mechanisms of cancer undetected on an individual gene level and allows discovery of new potential therapeutic targets. .
10aCell Line, Tumor10aCluster Analysis10aDisease Progression10aGene Expression Profiling10aGene Expression Regulation, Neoplastic10aGene Regulatory Networks10aHumans10aKaplan-Meier Estimate10aMetabolome10amutation10aNeoplasms10aOncogenes10aPhenotype10aPrognosis10aRNA, Small Interfering10aSequence Analysis, RNA10aTranscriptome10aTreatment Outcome1 aCubuk, Cankut1 aHidalgo, Marta, R1 aAmadoz, Alicia1 aPujana, Miguel, A1 aMateo, Francesca1 aHerranz, Carmen1 aCarbonell-Caballero, José1 aDopazo, Joaquin uhttps://www.clinbioinfosspa.es/content/gene-expression-integration-pathway-modules-reveals-pan-cancer-metabolic-landscape